276 related articles for article (PubMed ID: 32503225)
1. Pentadecanoic Acid, an Odd-Chain Fatty Acid, Suppresses the Stemness of MCF-7/SC Human Breast Cancer Stem-Like Cells through JAK2/STAT3 Signaling.
To NB; Nguyen YT; Moon JY; Ediriweera MK; Cho SK
Nutrients; 2020 Jun; 12(6):. PubMed ID: 32503225
[TBL] [Abstract][Full Text] [Related]
2. Loss of miR-6844 alters stemness/self-renewal and cancer hallmark(s) markers through CD44-JAK2-STAT3 signaling axis in breast cancer stem-like cells.
Prajapati KS; Kumar S
J Cell Biochem; 2023 Aug; 124(8):1186-1202. PubMed ID: 37436061
[TBL] [Abstract][Full Text] [Related]
3. 2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition
Liu LC; Wu YC; Kuo SC; Ho CT; Way TD; Chen ST
Anticancer Res; 2018 May; 38(5):2849-2859. PubMed ID: 29715108
[TBL] [Abstract][Full Text] [Related]
4. The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway.
Nourbakhsh M; Farzaneh S; Taghikhani A; Zarghi A; Noori S
Anticancer Agents Med Chem; 2020; 20(7):875-886. PubMed ID: 31893999
[TBL] [Abstract][Full Text] [Related]
5. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan.
Alaaeldin R; Ali FEM; Bekhit AA; Zhao QL; Fathy M
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431925
[TBL] [Abstract][Full Text] [Related]
7. Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF-7/SC Breast Cancer Cells.
To NB; Truong VN; Ediriweera MK; Cho SK
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232636
[TBL] [Abstract][Full Text] [Related]
8. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
Noori S; Nourbakhsh M; Farzaneh S; Zarghi A
Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949
[TBL] [Abstract][Full Text] [Related]
9. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
10. Polyphenols Extracted from
Ko YS; Jung EJ; Go SI; Jeong BK; Kim GS; Jung JM; Hong SC; Kim CW; Kim HJ; Lee WS
Molecules; 2020 Apr; 25(8):. PubMed ID: 32326231
[No Abstract] [Full Text] [Related]
11. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
[TBL] [Abstract][Full Text] [Related]
12. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling.
Zhao Q; Liu Y; Wang T; Yang Y; Ni H; Liu H; Guo Q; Xi T; Zheng L
Eur J Pharmacol; 2020 Oct; 884():173359. PubMed ID: 32738343
[TBL] [Abstract][Full Text] [Related]
13. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.
Balanis N; Wendt MK; Schiemann BJ; Wang Z; Schiemann WP; Carlin CR
J Biol Chem; 2013 Jun; 288(25):17954-67. PubMed ID: 23653350
[TBL] [Abstract][Full Text] [Related]
14. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
15. α-Hederin inhibits interleukin 6-induced epithelial-to-mesenchymal transition associated with disruption of JAK2/STAT3 signaling in colon cancer cells.
Sun D; Shen W; Zhang F; Fan H; Xu C; Li L; Tan J; Miao Y; Zhang H; Yang Y; Cheng H
Biomed Pharmacother; 2018 May; 101():107-114. PubMed ID: 29477470
[TBL] [Abstract][Full Text] [Related]
16. P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling.
Wang L; Zhan X; Shen X; Li M; Yang J; Yu W; Chen H; Jin B; Mao Z
Mol Cell Biochem; 2018 Sep; 446(1-2):137-148. PubMed ID: 29388151
[TBL] [Abstract][Full Text] [Related]
17. An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway.
Sulaiman NB; Mohan CD; Basappa S; Pandey V; Rangappa S; Bharathkumar H; Kumar AP; Lobie PE; Rangappa KS
Int J Oncol; 2016 Sep; 49(3):1221-9. PubMed ID: 27500741
[TBL] [Abstract][Full Text] [Related]
18. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
19. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
[TBL] [Abstract][Full Text] [Related]
20. Anti-Breast Cancer Activities of Ketoprofen-RGD Conjugate by Targeting Breast Cancer Stem-Like Cells and Parental Cells.
Noori S; Rajabi S; Tavirani MR; Shokri B; Zarghi A
Anticancer Agents Med Chem; 2021; 21(8):1027-1036. PubMed ID: 32900351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
